Home › Companies › Vaxcyte, Inc. › 2025-2026

Vaxcyte, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Vaxcyte, Inc.’s Form 8-K, filed 2026-06-16 (Item 5.07 on EDGAR). Page generated 04 October 2026.

7Reported items
350Asset managers
2,496Fund votes
2026-06-15Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Vaxcyte, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Vaxcyte, Inc.

These tallies are Vaxcyte, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-16 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Vaxcyte, Inc. — official shareholder meeting results, meeting held 2026-06-15
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Olivier Brandicourt, M.D.	116,370,183	--	--	16,643,897	4,354,403	Majority: yes
Elect Director: Halley Gilbert, J.D.	114,704,274	--	--	18,309,806	4,354,403	Majority: yes
Elect Director: Grant Pickering, M.B.A.	132,112,840	--	--	901,240	4,354,403	Majority: yes
Proposal 2: The ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.	137,230,032	137,589	862	--	--	Majority: yes
Proposal 3: The approval, on a non-binding, advisory basis of the compensation of the Company's named executive officers.	130,011,017	2,755,868	247,195	--	4,354,403	Passed

Source: Vaxcyte, Inc., Form 8-K, filed with the SEC on 2026-06-16 — read the filing on EDGAR.

How asset managers voted at the Vaxcyte, Inc. 2025-2026 meeting

Each item below shows how the 350 asset managers that disclosed a Vaxcyte, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Vaxcyte, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Combines 11 wordings of this item as funds reported it.

98% Passed · of votes cast

FOR 98%

FOR: 130,011,017AGAINST: 2,755,868

Vaxcyte, Inc.’s own tally for this item (“Proposal 3: The approval, on a non-binding, advisory basis of the compensation of the Company's named executive officers.”): 130,011,017 for, 2,755,868 against — passed, per its Form 8-K filed 2026-06-16 (Item 5.07). Of all 144,397,682 outstanding shares: 90% for, 2% against (92% of the company cast a for/against vote).

The 345 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 97%

FOR: 97.2%AGAINST: 1.8%ABSTAIN: 1.0%NOT VOTED: 0.0%

Largest asset managers voting on “Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.” at Vaxcyte, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	33,565,640	0	0	For
Janus Henderson	25,385,690	0	0	For
T. Rowe Price	20,470,867	261,048	0	For
Vanguard	16,676,306	18,999	0	For
RA CAPITAL MANAGEMENT, L.P.	11,474,599	0	0	For
BlackRock	9,803,708	0	0	For
JANUS INVESTMENT FUND	8,909,163	0	0	For
Wellington	5,043,516	0	0	For
State Street	4,118,786	2,553	0	For
Deep Track Capital, LP	4,080,248	0	0	For
WESTFIELD CAPITAL MANAGEMENT CO LP	3,235,381	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,223,717	0	0	For
Charles Schwab	2,814,933	0	0	For
Polar Capital Holdings Plc	2,692,450	0	0	For
Kynam Capital Management, LP	0	0	1,975,153	Abstain
MUTUAL FUND SERIES TRUST	1,367,753	0	0	For
DE Shaw	1,295,312	0	0	For
Federated Hermes	1,103,568	1,531	0	For
JENNISON ASSOCIATES LLC	1,095,689	4,606	0	For
Jackson National	1,071,397	0	0	For
Northern Trust	1,054,792	0	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	1,000,000	0	0	For
Aberdeen	983,683	0	0	For
Victory Capital	981,451	0	0	For
Capital Group	0	912,688	0	Against

Showing the 25 largest of 345 asset managers. See all 345 in the interactive database.

2. Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 137,230,032AGAINST: 137,589

Vaxcyte, Inc.’s own tally for this item (“Proposal 2: The ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 137,230,032 for, 137,589 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 144,397,682 outstanding shares: 95% for, 0.1% against (95% of the company cast a for/against vote).

The 94 asset managers below cast 99.9% of the shares they voted on this item FOR (70,430,834 for, 66 against).

FOR 99.9%

FOR: 70,430,834 (100.0%)AGAINST: 66 (0.0%)

Largest asset managers voting on “Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accoun” at Vaxcyte, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	16,760,051	0	For
Vanguard	15,629,499	0	For
JANUS INVESTMENT FUND	8,909,163	0	For
T. Rowe Price	7,896,178	0	For
BlackRock	5,381,969	0	For
State Street	1,702,535	66	For
Charles Schwab	1,403,438	0	For
MUTUAL FUND SERIES TRUST	1,367,753	0	For
Jackson National	1,071,397	0	For
Capital Group	912,688	0	For
Prudential/PGIM	837,011	0	For
HARBOR FUNDS	811,895	0	For
JPMorgan	573,638	0	For
Federated Hermes	538,085	0	For
Victory Capital	485,539	0	For
Equitable	468,717	0	For
JANUS ASPEN SERIES	339,889	0	For
American Century	277,976	0	For
TIAA	261,821	0	For
ALGER FUNDS	256,531	0	For
Bridge Builder Trust	248,308	0	For
Hartford	238,418	0	For
John Hancock	228,055	0	For
AIG/SunAmerica	225,452	0	For
Voya	223,225	0	For

Showing the 25 largest of 94 asset managers. See all 94 in the interactive database.

3. Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Olivier Brandicourt, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%

FOR: 116,370,183WITHHELD: 16,643,897

Vaxcyte, Inc.’s own tally for this item (“Elect Director: Olivier Brandicourt, M.D.”): 116,370,183 for, 16,643,897 withheld, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 144,397,682 outstanding shares: 81% for, 12% withheld (92% of the company cast a for/withheld vote).

The 93 asset managers below cast 100% of the shares they voted on this item FOR (66,995,716 for, 0 against).

FOR 95%

FOR: 66,995,716 (95.1%)ABSTAIN: 3,428,525 (4.9%)

Largest asset managers voting on “Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until t” at Vaxcyte, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	16,758,851	1,200	For
Vanguard	15,629,465	34	For
JANUS INVESTMENT FUND	8,778,700	130,463	For
T. Rowe Price	7,896,178	0	For
BlackRock	5,381,969	0	For
State Street	1,686,364	16,237	For
Charles Schwab	1,403,438	0	For
MUTUAL FUND SERIES TRUST	1,367,753	0	For
Jackson National	939,328	132,069	For
Capital Group	912,688	0	For
Prudential/PGIM	836,471	540	For
HARBOR FUNDS	0	811,895	Abstain
JPMorgan	573,638	0	For
Federated Hermes	538,085	0	For
Victory Capital	567	484,972	Abstain
Equitable	376,188	92,529	For
JANUS ASPEN SERIES	339,889	0	For
American Century	0	277,976	Abstain
TIAA	261,821	0	For
ALGER FUNDS	0	256,531	Abstain
Bridge Builder Trust	248,308	0	For
Hartford	238,418	0	For
John Hancock	135,108	92,947	For
AIG/SunAmerica	0	225,452	Abstain
Voya	223,225	0	For

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

4. Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Halley Gilbert, J.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 9 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%14%

FOR: 114,704,274WITHHELD: 18,309,806

Vaxcyte, Inc.’s own tally for this item (“Elect Director: Halley Gilbert, J.D.”): 114,704,274 for, 18,309,806 withheld, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 144,397,682 outstanding shares: 79% for, 13% withheld (92% of the company cast a for/withheld vote).

The 93 asset managers below cast 100% of the shares they voted on this item FOR (66,698,205 for, 0 against).

FOR 95%

FOR: 66,698,205 (94.7%)ABSTAIN: 3,726,036 (5.3%)

Largest asset managers voting on “Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until t” at Vaxcyte, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	16,758,851	1,200	For
Vanguard	15,622,393	7,106	For
JANUS INVESTMENT FUND	8,778,700	130,463	For
T. Rowe Price	7,896,178	0	For
BlackRock	5,381,969	0	For
State Street	1,686,364	16,237	For
Charles Schwab	1,403,438	0	For
MUTUAL FUND SERIES TRUST	1,367,753	0	For
Jackson National	939,328	132,069	For
Capital Group	912,688	0	For
Prudential/PGIM	836,471	540	For
HARBOR FUNDS	0	811,895	Abstain
JPMorgan	573,638	0	For
Federated Hermes	538,085	0	For
Victory Capital	567	484,972	Abstain
Equitable	376,188	92,529	For
JANUS ASPEN SERIES	339,889	0	For
American Century	0	277,976	Abstain
TIAA	261,821	0	For
ALGER FUNDS	0	256,531	Abstain
Bridge Builder Trust	248,308	0	For
Hartford	238,418	0	For
John Hancock	135,108	92,947	For
AIG/SunAmerica	0	225,452	Abstain
Voya	0	223,225	Abstain

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

5. Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Grant E. Pickering, M.B.A.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 9 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%

FOR: 132,112,840WITHHELD: 901,240

Vaxcyte, Inc.’s own tally for this item (“Elect Director: Grant Pickering, M.B.A.”): 132,112,840 for, 901,240 withheld, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 144,397,682 outstanding shares: 91% for, 0.7% withheld (92% of the company cast a for/withheld vote).

The 93 asset managers below cast 100% of the shares they voted on this item FOR (70,107,034 for, 0 against).

FOR 99.5%

FOR: 70,107,034 (99.5%)ABSTAIN: 317,207 (0.5%)

Largest asset managers voting on “Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until t” at Vaxcyte, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	16,760,051	0	For
Vanguard	15,629,497	2	For
JANUS INVESTMENT FUND	8,909,163	0	For
T. Rowe Price	7,896,178	0	For
BlackRock	5,381,969	0	For
State Street	1,702,601	0	For
Charles Schwab	1,403,438	0	For
MUTUAL FUND SERIES TRUST	1,367,753	0	For
Jackson National	1,053,252	18,145	For
Capital Group	912,688	0	For
Prudential/PGIM	836,471	540	For
HARBOR FUNDS	811,895	0	For
JPMorgan	573,638	0	For
Federated Hermes	538,085	0	For
Victory Capital	485,539	0	For
Equitable	376,188	92,529	For
JANUS ASPEN SERIES	339,889	0	For
American Century	277,976	0	For
TIAA	261,821	0	For
ALGER FUNDS	256,531	0	For
Bridge Builder Trust	248,308	0	For
Hartford	238,418	0	For
John Hancock	166,585	61,470	For
AIG/SunAmerica	225,452	0	For
Voya	223,225	0	For

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

6. Election of Class III Directors

DIRECTOR ELECTIONS

All nominees (reported as one line). These filers reported the election of directors as a single line covering every nominee. It is not attributed to any one director, and no share total is shown for it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR.

FOR: 100.0%

Largest asset managers voting on “Election of Class III Directors” at Vaxcyte, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Advisors' Inner Circle Fund III	6,489	0	0	0	For
Meeder Funds	170	0	0	0	For

7. SAY ON PAY

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

98% Passed · of votes cast

FOR 98%

FOR: 130,011,017AGAINST: 2,755,868

The 2 asset managers below cast 100% of the shares they voted on this item FOR (54 for, 0 against).

FOR 100%

FOR: 54 (100.0%)

Largest asset managers voting on “SAY ON PAY” at Vaxcyte, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
ArchPoint Investors	54	0	0	0	For
Ikarian Capital, LLC	0	0	0	0	--

Largest Vaxcyte, Inc. shareholders voting in 2025-2026

Ranked by the number of Vaxcyte, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 144,397,682 shares outstanding at the time of that meeting.

Top Vaxcyte, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	23.25%
2	Janus Henderson	17.58%
3	T. Rowe Price	14.36%
4	Vanguard	11.56%
5	RA CAPITAL MANAGEMENT, L.P.	7.95%
6	BlackRock	6.79%
7	JANUS INVESTMENT FUND	6.17%
8	Wellington	3.49%
9	State Street	2.85%
10	Deep Track Capital, LP	2.83%

Reported Vaxcyte, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Vaxcyte, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
JANUS HENDERSON GROUP PLC	11.48%	13G
FMR (Fidelity)	11.42%	13F
FMR LLC	9.09%	DEF14A
RA Capital Management, L.P.	8.99%	13G
T. Rowe Price Investment Management, Inc.	7.82%	13G
BlackRock	7.60%	13F
Wellington Management	3.89%	13F
State Street	3.08%	13F
D.E. Shaw	1.98%	13F
Grant E. Pickering	1.53%	DEF14A

Percentages above are of 144,397,682 shares outstanding, as reported by Vaxcyte, Inc. on its Form 10-Q dated 2026-05-04 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Vaxcyte, Inc.’s 10-Q dated 2026-05-04. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Vaxcyte, Inc.'s shareholder meeting held 2026-06-15, in the 2025-2026 proxy season, 350 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,496 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on a non-binding, advisory basis, of the compensation of the Company's named… — the proposal passed with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Vaxcyte, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-16.

Vaxcyte, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).